SCHEMBL845282

SCHEMBL845282

Cn1cccc1C(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)c3cccn3C)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 3/20 0.45
MAPK1 P28482 2/20 0.45
HTT P42858 1/20 0.45
KCNH2 Q12809 1/20 0.44
MAPT P10636 1/20 0.44
HPGDS O60760 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RHOC P08134 1/20 0.44
RHOA P61586 1/20 0.44
NPC1 O15118 1/20 0.43
PABPC1 P11940 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845341 0.83 CYP2C9 (0.43) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL845237 0.83 ALDH1A1 (0.45) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL845176 0.81 CYP2C9 (0.43) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL845300 0.81 CYP2C9 (0.54) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL845008 0.80 ALDH1A1 (0.54) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL873200 0.79 RHOC (0.48) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL844890 0.79 KCNH2 (0.51) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL844996 0.79 CYP2C9 (0.50) CYP2C9CYP2C19ALDH1A1MAPK1HTT
SCHEMBL845292 0.79 KMT2A (0.47) CYP2C9CYP2C19ALDH1A1HTTMEN1
SCHEMBL845083 0.79 HSD11B1 (0.53) CYP2C9CYP2C19ALDH1A1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed